Mortality rates among patients with schizophrenia and tardive dyskinesia

Journal of Clinical Psychopharmacology

Volumn 29, Issue 1, 2009, Pages 5-8

  Chong, Siow Ann ^a   Tay, Jenny A M ^a   Subramaniam, Mythily ^a   Pek, Elaine ^a   MacHin, David ^b  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Mortality; Schizophrenia; Tardive dyskinesia

Indexed keywords

ADULT; AGED; ARTICLE; ASIAN; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SURVIVAL RATE; SURVIVAL TIME; TARDIVE DYSKINESIA; AGE; COMORBIDITY; DYSKINESIA; MIDDLE AGED;

NEUROLEPTIC AGENT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; COMORBIDITY; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SURVIVAL RATE;

EID: 62649152952     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181929f94     Document Type: Article

References (28)

1. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 1997;171:502-508.
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.
3. Kane JM, Smith J. Tardive dyskinesia: prevalence of risk factors, 1959-1979. Arch Gen Psychiatry. 1982;39:486-487.
4. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701-715.
5. Woerner M, Kane JM, Lieberman J, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol. 1991;11:34-42.
6. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol. 2000;20:188-194.
7. Chong SA, Mahendran R, Machin D, et al. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol. 2002;22:26-30.
8. Guy W. Assessment Manual for Psychopharmacology. Publication (ADH) 76-338. Washington, DC: US Department of Health, Education, and Welfare, ECDEU; 1976:534-537.
9. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
10. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
11. Machin D, Cheung YB, Parmar MK. Survival Analysis: A Practical Approach. 2nd ed. Chichester, England: Wiley; 2006.
12. Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand. 1987;75:74-77.
13. Woerner M, Alvir JMJ, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521-1528.
14. Woerner MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150:966-968.
15. Gough SC, O'Donnovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol. 2005;19(6 suppl):47-55.
16. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry. 2003;48:345-347.
17. Dean CE, Thuras PD. Mortality and tardive dyskinesia: a long-term study utilizing the national death index. Movement Disorders. 2005;20(suppl 10):S49.
18. Mehta D, Mallya A, Volavka J. Mortality of patients with tardive dyskinesia. Am J Psychiatry. 1978;135:371-372.
19. Yassa R, Mohelsky H, Dimitry R, et al. Mortality rate in tardive dyskinesia. Am J Psychiatry. 1984:141:1018-1019.
20. Yagi G, Takamiya M, Kanba S, et al. Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study. Keio J Med. 1989;38:70-72.
21. Inada T, Koshiishi M, Ohnishi K, et al. The life expectancy of schizophrenic with tardive dyskinesia. Hum Psychopharmacol Clin Exp. 1992;7:249-254.
22. Correll CU, Leucht S, Kane J. Lower risk of tardive dyskinesia associated with second generation antipsychotics. A systematic review of one year studies. Am J Psychiatry. 2004;161:414-425.
23. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus statement: consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
24. Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry. 2006;163(7):1132-1134.
25. Lieberman JA, Stroup ST, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
26. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
27. Emsley RA, Oosthuizen PP, Joubert AF, et al. Treatment of schizophrenia in low-income countries. Int J of Neuropsychopharmacol. 1992;2:321-325.
28. Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 2004;58:178-183.